record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundexperimental · manual state transition; placebo-controlled clinical trial where source reports control arm · Homo sapiens
proof impact
packet context5 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition; placebo-controlled clinical trial where source reports control arm
evidence type
experimental
species
Homo sapiens
evidence spans
Verubecestat failed to improve cognition or function in mild-to-moderate Alzheimer's disease despite BACE1 target engagement.
Egan et al. 2018 NEJM, EPOCH · curator_source · 10.1056/NEJMoa1706441
conditions
Provenance
source title
Egan et al. 2018 NEJM, EPOCH
doi
10.1056/NEJMoa1706441
journal
New England Journal of Medicine
authors
reviewer:will-blair-bot
source record
declaredvs_10993e8203d14020doi:10.1056/NEJMoa1706441 · 10.1056/NEJMoa1706441
inspect source →
source record
declaredvs_e1be38b966c19185doi:10.1056/NEJMoa1706441 · 10.1056/NEJMoa1706441 · 29719179
inspect source →
Verubecestat failed to improve cognition or function in mild-to-moderate Alzheimer's disease despite BACE1 target engagement.
vs_10993e8203d14020 · source:Egan et al. 2018 NEJM, EPOCH|section:curator_source · manual_curation
outgoing
vf_afddbeabc19efa09amyloid-pathway target engagement did not translate to clinical benefit in this BACE program
incoming
supports · vf_0767356cc73a6387
replicates · vf_247ab84f7a601b89
supports · vf_3d75299a343a2fc8
extends · vf_4f57348016eea37b
events
vev_256faa62a301a60cfinding.reviewedReviewed as amyloid-pathway translation tension, not as a direct antibody contradiction.
reviewer:will-blair-bot · 2026-05-06
vev_54acd1bb09b776e3finding.caveatedBACE failures should not be treated as proof that every amyloid-lowering approach fails.
reviewer:will-blair-bot · 2026-05-06
vev_d5fc4a90bfc01935finding.caveatedDecision-console scope: verubecestat is used here as a failed BACE program exemplar; the correction path should not generalize this single result to every amyloid-lowering approach.
reviewer:will-blair-bot · 2026-05-06
vev_e18f2033f68a422ffinding.reviewedReviewed for decision-console use: failed BACE program claim is scoped to verubecestat EPOCH-style clinical failure, not all anti-amyloid mechanisms.
reviewer:will-blair-bot · 2026-05-06
vev_ea98c3207e67eb18finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_371b4e01866e4d94finding.reviewReviewed for decision-console use: failed BACE program claim is scoped to verubecestat EPOCH-style clinical failure, not all anti-amyloid mechanisms.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_47e89f04337c7786finding.caveatDecision-console scope: verubecestat is used here as a failed BACE program exemplar; the correction path should not generalize this single result to every amyloid-lowering approach.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_7420a100feb4fe3ffinding.caveatBACE failures should not be treated as proof that every amyloid-lowering approach fails.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_942ae202f8fa3144finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_da34872d64ddd2c9finding.reviewReviewed as amyloid-pathway translation tension, not as a direct antibody contradiction.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.